Autoanticorps et diagnostic prècoce des cancers

Translated title of the contribution: Serum autoantibodies profiling and early-stage cancer detection

Caroline Desmetz, Jérôme Lacombe, Alain Mange, Thierry Maudelonde, Jérôme Solassol

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


It is now well established that an immune response to cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer. During these past few years, proteomic approaches have been developed to identify tumor-associated antigens and their cognate autoantibodies. Detection of a panel of serum autoantibodies has thus been proposed as a new method for early cancer diagnosis. Early detection seems to be particularly adequate in high-risk populations, such as heavy smokers for lung cancer or in women with high mammographic density for breast cancer. In this review, we highlight the features of serum autoantibody biomarkers and outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures, using the examples of lung and breast cancer. Finally, we discuss the challenges remaining for clinical validation. 0.

Translated title of the contributionSerum autoantibodies profiling and early-stage cancer detection
Original languageFrench
Pages (from-to)633-638
Number of pages6
Issue number6-7
StatePublished - Jun 2011
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Serum autoantibodies profiling and early-stage cancer detection'. Together they form a unique fingerprint.

Cite this